Llwytho...
EXTH-19. COMBINATION OF IN VITRO TUMOR TREATING FIELDS AND TEMOZOLOMIDE DECREASE PROLIFERATION IN PATIENT-DERIVED GLIOBLASTOMA CELL LINES
BACKGROUND: Tumor treating fields (TTFields) are FDA-approved for treatment of newly-diagnosed and recurrent glioblastoma. Adding TTFields therapy to standard-of-care temozolomide (TMZ) extended progression-free survival and overall survival in newly-diagnosed glioblastoma patients. In this study, c...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Neuro Oncol |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692458/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.314 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|